PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 21, 2023 /PRNewswire/ --  PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or "Lucid Diagnostics"), a commercial-stage cancer prevention diagnostics company, today announced their participation in the 2023 Cantor Fitzgerald Global Healthcare Conference in New York City.

Lucid Diagnostics is developing a revolutionary non-invasive, office-based diagnostic test for biomarkers to esophageal cancer. (PRNewsfoto/Lucid Diagnostics)

Lishan Aklog, M.D., PAVmed and Lucid's Chairman & Chief Executive Officer, and Dennis McGrath, PAVmed's President and Chief Financial Officer and Lucid's Chief Financial Officer, will participate in a panel presentation on Wednesday, September 27, 2023, at 8:00 a.m. EDT.

About PAVmed and its Subsidiaries

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard^® Esophageal DNA Test and EsoCheck^® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other majority-owned subsidiary, Veris Health Inc., is a private, commercial-stage digital health company focused on enhancing cancer care through remote monitoring and virtual care using the Veris Cancer Care Platform. Veris is concurrently developing a fully implantable, intelligent, physiologic monitor for attachment and coimplantation with a vascular access port that will further enhance the clinical and commercial value of the platform by providing physiologic data to the care providers, independent of patient compliance.

For more and for more information about PAVmed, please visit pavmed.com.

For more information about Lucid Diagnostics, please visit luciddx.com.

For more information about Veris Health, please visit verishealth.com.

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-and-lucid-diagnostics-to-participate-in-panel-presentation-at-the-2023-cantor-fitzgerald-global-healthcare-conference-301934843.html

SOURCE Lucid Diagnostics